MyChesCo on MSN21 小时
Breakthrough Gene Therapy OCU410 Could Save Millions from Vision Loss – Phase 2 Milestone ...
Ocugen, Inc. (NASDAQ: OCGN) has announced the completion of dosing in the Phase 2 portion of its ArMaDa clinical trial for ...
PulseSight Therapeutics Announces First Close of its Series A Financing to Fund Clinical ...
PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces the first close of its ...
Ocugen shares rise as H.C. Wainwright lifts price target to $8
H.C. Wainwright analyst raised the price target on Ocugen, Inc. (NASDAQ:OCGN) to $8.00, up from the previous $7.00, while maintaining a Buy rating on the stock. Currently trading at $0.66, the stock ...
The Goldman Sachs Group Downgrades REGENXBIO (NASDAQ:RGNX) to Neutral
REGENXBIO (NASDAQ:RGNX – Get Free Report) was downgraded by analysts at The Goldman Sachs Group from a “buy” rating to a “neutral” rating in a report issued on Tuesday, MarketBeat reports. They ...
Molecular Cytogenetics Market Size to Expand USD 6.9 Bn by 2034
The global molecular cytogenetics market size is calculated at USD 2.78 billion in 2025 and is expected to reach around USD 6 ...